Intrathecal treatment of anti-N-Methyl-D-aspartate receptor encephalitis in children.

Dev Med Child Neurol

Pediatric Neurology Department, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; National Referral Center for Neuro-Inflammatory Diseases in Children, University Paris-Sud, Le Kremlin-Bicêtre, France.

Published: January 2015

Anti-NDMA receptor (NMDAR) encephalitis is an auto-immune condition. There is no uniformly agreed treatment strategy for the disorder in children. We report the use of intrathecal treatment with methotrexate and methylprednisolone in three children (one male, two females, age 10y, 11y, and 14y) with anti-NMDAR encephalitis, who did not respond to steroids, plasmapheresis, or rituximab. There was significant clinical improvement and stabilization of the anti-NMDAR antibody titers in cerebrospinal fluid (CSF) and blood in two patients. In the third patient, although anti-NMDAR antibody titers in CSF decreased, clinical recovery was less satisfactory. Intrathecal treatment with methotrexate and methylprednisolone seems to be a promising alternative treatment for some paediatric cases of resistant anti-NMDAR encephalitis.

Download full-text PDF

Source
http://dx.doi.org/10.1111/dmcn.12545DOI Listing

Publication Analysis

Top Keywords

intrathecal treatment
12
treatment methotrexate
8
methotrexate methylprednisolone
8
anti-nmdar encephalitis
8
anti-nmdar antibody
8
antibody titers
8
treatment anti-n-methyl-d-aspartate
4
anti-n-methyl-d-aspartate receptor
4
encephalitis
4
receptor encephalitis
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!